Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Xoma decides downsizing has its limits

Xoma decides downsizing has its limits

Xoma Corp.'s most recent downsizing may test the limits of how far an established company can cut back and still maintain the requisite skills to move products through development.

The Berkeley, Calif., company last week said it was reducing its workforce by 37 percent, from 229 to

Read the full 556 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers